Impact of T-cell Affinity in Bispecific Therapy in R/R MM
Noopur Raje, MD, discusses the role of T-cell affinity in bispecific therapy for patients with relapsed/refractory multiple myeloma and how it impacts treatment practices.
EP: 1.Significance of GPRC5D as a Target for R/R MM
EP: 2.Long-Term Follow-Up of MonumenTAL-1
EP: 3.MonumenTAL-1: Efficacy and Safety Data
EP: 4.Broader Implications and Current Trials of GPRC5D-Targeted Treatments in Relapsed/Refractory Multiple Myeloma
EP: 5.Overview of MonumenTAL-2 and MonumenTAL-3
EP: 6.Evaluating Combination Strategies in R/R MM: TRIMM-2, TRIMM-3, MajesTEC-3
EP: 7.Exploring GPRC5D as an Important Target for Multiple Myeloma
EP: 8.Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5
EP: 9.Implications of Combination Regimens for R/R MM
EP: 10.Overview of Recent Updates in Bispecific Therapy in R/R MM
Now Viewing
EP: 11.Impact of T-cell Affinity in Bispecific Therapy in R/R MM
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
